Synapse

← Charles M. Perou

Papers by Charles M. Perou

Page 4 · newest first

  1. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancerJournal for ImmunoTherapy of Cancer · 2022
  2. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerSHILAP Revista de lepidopterología · 2022
  3. Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 TherapeuticsCancer Research Communications · 2021
  4. Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast CancersCancer Research · 2021
  5. Joint and individual analysis of breast cancer histologic images and genomic covariatesThe Annals of Applied Statistics · 2021
  6. Molecular analysis of TCGA breast cancer histologic typesCell Genomics · 2021
  7. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial2021
  8. Anti–PD-1 Checkpoint Therapy Can Promote the Function and Survival of Regulatory T CellsThe Journal of Immunology · 2021
  9. Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancerNature Communications · 2021
  10. MultiK: an automated tool to determine optimal cluster numbers in single-cell RNA sequencing dataGenome biology · 2021
  11. Entinostat induces antitumor immune responses through immune editing of tumor neoantigensJournal of Clinical Investigation · 2021
  12. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapyEBioMedicine · 2021
  13. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cellsNature Communications · 2021
  14. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics2021
  15. FOXA1 overexpression suppresses interferon signaling and immune response in cancerJournal of Clinical Investigation · 2021
  16. Genome-Wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk Among 62,370 Women2021
  17. Rare copy number variants (CNVs) and breast cancer risk2021
  18. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036npj Breast Cancer · 2021
  19. Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accidentScience · 2021
  20. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancerBreast Cancer Research and Treatment · 2021
  21. Gene-level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients2021
  22. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumorsBreast Cancer Research · 2021
  23. Inherited predisposition to breast cancer in the Carolina Breast Cancer Studynpj Breast Cancer · 2021
  24. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features2020
  25. Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer2020
  26. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma2020
  27. The molecular portraits of breast tumors are conserved across microarray platforms2020
  28. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival2020
  29. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast CancerJournal of Clinical Oncology · 2020
  30. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological FeaturesJNCI Cancer Spectrum · 2020
  31. Receiver operating characteristic curves and confidence bands for support vector machinesBiometrics · 2020
  32. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast CancerClinical Cancer Research · 2020
  33. Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast CancerCancer Discovery · 2020
  34. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic diseaseJournal of Clinical Investigation · 2020
  35. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays2020
  36. An Analysis of the Sensitivity of Proteogenomic Mapping of Somatic Mutations and Novel Splicing Events in Cancer2020
  37. A framework for transcriptome-wide association studies in breast cancer in diverse study populationsGenome biology · 2020
  38. Virus expression detection reveals RNA-sequencing contamination in TCGASHILAP Revista de lepidopterología · 2020
  39. Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approachesBMC Bioinformatics · 2020
  40. Microscaled proteogenomic methods for precision oncologyNature Communications · 2020
  41. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline UpdateJournal of Clinical Oncology · 2020
  42. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline UpdateArchives of Pathology & Laboratory Medicine · 2020
  43. Genetic determinants of the molecular portraits of epithelial cancersNature Communications · 2019
  44. SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing referencesBriefings in Bioinformatics · 2019
  45. Borderline Estrogen Receptor–Positive Breast Cancers in Black and White WomenJNCI Journal of the National Cancer Institute · 2019
  46. Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancerNature Communications · 2019
  47. Microscaled Proteogenomic Methods for Precision Oncology2019
  48. Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classificationsBreast Cancer Research and Treatment · 2019
  49. A Framework for Transcriptome-Wide Association Studies in Breast Cancer in Diverse Study Populations2019
  50. SCDC: Bulk Gene Expression Deconvolution by Multiple Single-Cell RNA Sequencing References2019